全球医疗健康及生命科学行业继续面临动态的挑战和变化，包括力度持续加大的政府监管、定价压力、日渐加剧的竞争、科学突破和技术创新，与此同时，还必须要满足客户和股东的需求。

面对医疗健康及生命科学行业的需求，谢尔曼•思特灵致力于向客户提供有关公司治理、合规、另类融资、并购、竞争、战略联盟、IPO、争议解决、薪酬及网络安全问题的有洞察力的、以业务为导向的意见和建议。

凭借我们在发达市场和新兴市场拥有的丰富经验，我们理解客户的业务以及日新月异的医疗健康行业，并且提供符合客户业务发展优先性的具有实用性的解决方案。本所部署在亚洲、中东、欧洲和北美洲的律师们服务于各种规模的医疗健康及生命科学企业— 从生物技术初创企业到大型跨国制药公司。

• CVS Health | Represented CVS Health in its $69 billion industry-transforming acquisition of Aetna.
• Boston Scientific | Represented Boston Scientific in its $5.1 billion acquisition of BTG plc.
• Genmab A/S | Advised Genmab A/S in connection with its $506 million initial public offering and listing of American Depositary Shares (ADSs) on the Nasdaq, the largest-ever biotech offering by a European issuer on a U.S. exchange.
• GlaxoSmithKline | Represented global pharmaceutical company GlaxoSmithKline in its $5.1 billion acquisition of oncology-focused biopharmaceutical company Tesaro.
• Golden Meditech | Represented Hong Kong-listed Golden Meditech on its $830 million sale of stake in China Cord Blood.
• Novartis | Represented Novartis on its $3.9 billion acquisition of Nasdaq-listed Advanced Accelerator Applications, which won “M&A Deal of the Year” at the IFLR Europe Awards 2019.
• Sun Pharmaceuticals | Represented Sun Pharmaceuticals, one of the largest specialty generic pharmaceutical companies, in its $4 billion acquisition of Ranbaxy Laboratories, Ltd.
• WuXi AppTec | Represented the underwriters on the $1 billion global offering and initial public offering of WuXi AppTec Co., Ltd on the Main Board of the Stock Exchange of Hong Kong Limited.